Intraocular fluid composition analysis

Intraocular fluid composition analysis - Intraocular fluid composition analysis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020718

Enrollment

5000

Registered

2016-01-24

Start date

2013-07-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All cases to pierce the surgical instruments or injection needle into the eye for therapeutic purposes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: It is necessary to perform surgery or injection to the eye.

Exclusion criteria

Exclusion criteria: Without informed consent.

Design outcomes

Primary

Measure	Time frame
Beta NGF/NGFB, IL-15, CD40 ligand, IL-16/LCF, EGF, IL-17A/CTLA8, ENA-78/CXCL5, IL-17F/ML-1, Eotaxin/CCL11, IL-20, FGF basic, IP-10/CXCL10, Fractalkine, ITAC/CXCL11, G-CSF/CSF-3, Leptin/LEP, GM-CSF/CSF-2, MCP-1/CCL2, GRO alpha/CXCL1, MCP-3/CCL7, IFN alpha2, MCSF/CSF-1, IFN beta, MIG/CXCL9, IFN gamma, MIP-1 alpha/CCL3, IL-1 alpha, MIP-1 beta/CCL-4, IL-1 beta, MIP-3 alpha/CCL20, IL-1RA/IL1R1, PAI-1/Serpin E1, IL-2, PDGFBB, IL-4, RANTES/CCL5, IL-5, Resistin/ADSF, IL-6, SAA, IL-7, TGF alpha, IL-8/CXCL8, TGF beta1, IL-9, TNF alpha, IL-10/CSIF, TNF beta, IL-12( p40), TRAIL/TNFSF10, IL-12(p70), VEGF-A, IL-13, Adiponectin, IL-31, BDNF, LIF, BLC/CXCL13, MIF, BlyS/BAFF/CD257, MPO, CTACK/CCL27, OPG, E-selectin/CD62E, OSM, Eotaxin2/CCL24, PIGF-1, Eotaxin3/CCL26, RANKL/TNFSF11, FAS/TNFRSF6, SAP/Pentraxin2, FAS Ligand/TNFSF6, SCF/MGF, Granzyme B, SCGF-beta/CLEC11A, ICAM-1/CD54, SDF-1/CXCL12, IFN omega/IFNW1, SLP1, IL-2 RA/CD25, Survivin/BIRC5, IL-3, TNFRI/TNFRSF1A, IL-21, TNFRII/TNFRSF1B, IL-22/IL-TIF, TPO/Thrombopoietin, IL-23 p19, TSLP, IL-27, VCAM-1/CD106, IL-29, MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, IL-6, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-33,P-Selectin/CD62, sCD40L, total IgG, rubella IgG, tronbin, lipid mediator SIP,ATX,LPA,LPC, Th1/Th2, Aflibercept, Brolucizumab, farisimab, ranibizumab, bevacizumab	—

Measure

Time frame

Beta NGF/NGFB, IL-15, CD40 ligand, IL-16/LCF, EGF, IL-17A/CTLA8, ENA-78/CXCL5, IL-17F/ML-1, Eotaxin/CCL11, IL-20, FGF basic, IP-10/CXCL10, Fractalkine, ITAC/CXCL11, G-CSF/CSF-3, Leptin/LEP, GM-CSF/CSF-2, MCP-1/CCL2, GRO alpha/CXCL1, MCP-3/CCL7, IFN alpha2, MCSF/CSF-1, IFN beta, MIG/CXCL9, IFN gamma, MIP-1 alpha/CCL3, IL-1 alpha, MIP-1 beta/CCL-4, IL-1 beta, MIP-3 alpha/CCL20, IL-1RA/IL1R1, PAI-1/Serpin E1, IL-2, PDGFBB, IL-4, RANTES/CCL5, IL-5, Resistin/ADSF, IL-6, SAA, IL-7, TGF alpha, IL-8/CXCL8, TGF beta1, IL-9, TNF alpha, IL-10/CSIF, TNF beta, IL-12( p40), TRAIL/TNFSF10, IL-12(p70), VEGF-A, IL-13, Adiponectin, IL-31, BDNF, LIF, BLC/CXCL13, MIF, BlyS/BAFF/CD257, MPO, CTACK/CCL27, OPG, E-selectin/CD62E, OSM, Eotaxin2/CCL24, PIGF-1, Eotaxin3/CCL26, RANKL/TNFSF11, FAS/TNFRSF6, SAP/Pentraxin2, FAS Ligand/TNFSF6, SCF/MGF, Granzyme B, SCGF-beta/CLEC11A, ICAM-1/CD54, SDF-1/CXCL12, IFN omega/IFNW1, SLP1, IL-2 RA/CD25, Survivin/BIRC5, IL-3, TNFRI/TNFRSF1A, IL-21, TNFRII/TNFRSF1B, IL-22/IL-TIF, TPO/Thrombopoietin, IL-23 p19, TSLP, IL-27, VCAM-1/CD106, IL-29, MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13, IL-6, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-33,P-Selectin/CD62, sCD40L, total IgG, rubella IgG, tronbin, lipid mediator SIP,ATX,LPA,LPC, Th1/Th2, Aflibercept, Brolucizumab, farisimab, ranibizumab, bevacizumab

—

Secondary

Measure	Time frame
clinical course	—

Countries

Japan

Contacts

Public ContactHidenori Takahashi

Jichi Medical University Ophthalmology

takahah-tky@umin.ac.jp0285-58-7382

Outcome results